Skip to main content
XTL Biopharmaceuticals Ltd. logo

XTL Biopharmaceuticals Ltd. — Investor Relations & Filings

Ticker · XTLB ISIN · IL0010854979 LEI · 529900NDDXEAPTUTXP41 TA Manufacturing
Filings indexed 1,223 across all filing types
Latest filing 2008-01-18 Director's Dealing
Country IL Israel
Listing TA XTLB

About XTL Biopharmaceuticals Ltd.

https://www.xtlbio.com

XTL Biopharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the acquisition and development of pharmaceutical products to address unmet clinical needs. The company's primary therapeutic area of interest is autoimmune diseases. Its development pipeline has included proprietary drug candidates for conditions such as Systemic Lupus Erythematosus (SLE).

Recent filings

Filing Released Lang Actions
Director's Dealing 2008
Director's Dealing
2008-01-18 English
Director's Dealing 2008
Director's Dealing
2008-01-15 English
SC 13G
Major Shareholding Notification
2008-01-14 English
Director's Dealing 2008
Director's Dealing
2008-01-11 English
Director's Dealing 2008
Director's Dealing
2008-01-08 English
Investor Presentation 2008
Investor Presentation Classification · 90% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, XTL Biopharmaceuticals Ltd. It announces the company's CEO will present at the 26th Annual JPMorgan Healthcare Conference, including details about the presentation and webcast. The document does not contain financial statements or detailed financial analysis, nor does it report earnings or management discussion. It is primarily an announcement of an upcoming investor presentation event. Given the content and context, this fits best as an Investor Presentation (IP) announcement rather than the presentation materials themselves. However, since the document is a Form 6-K and announces the presentation, it aligns with the Investor Presentation category. The document length is 3139 characters, which is short but contains substantive information about the presentation event, not just a brief notice. Therefore, the classification is Investor Presentation (IP) with high confidence.
2008-01-07 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.